Tilray's Stock Is Down Over 50% This Year. Has It Become a Bargain Buy?

Tilray reported $633.7M net revenue for the nine months ended Feb. 28 (+6% YoY), but gross profit fell 2% and it posted an operating loss of $46.6M. Despite heavy acquisition-led growth, the article highlights unprofitability and deteriorating margins, noting the stock is down over 50% this year and down 97% over five years. Overall, it frames TLRY as a high-risk “cheap” stock with limited near-term catalysts.

Analysis

This is less a growth story than a capital-allocation story: when revenue rises slower than gross profit falls, the market stops paying for size and starts penalizing dilution risk, integration drag, and low-quality mix. In cannabis, that matters because the whole sector trades on future U.S. optionality; if one of the most visible names can’t show operating leverage now, the multiple on peers like CGC, CRON, and the broader MJ basket can compress as investors re-rate “option value” downward.

The immediate path is more about sentiment than fundamentals: retail will likely buy dips, but absent a policy catalyst the stock can keep bleeding as each quarter confirms that acquisitions are not fixing unit economics. Over 1-3 months, the key watch item is whether management can slow cash burn and stabilize margin; if not, the market will increasingly price in further equity issuance or asset sales, which would be bearish for per-share value even if top-line growth continues.

Contrarianly, the consensus is treating legalization as a free call option, but the timing mismatch is the problem: the option can expire long before the law changes. The move is probably not “cheap” so much as a distressed equity with embedded financing overhang; the thesis breaks only if there is a credible U.S. reform headline or a sharp, sustained improvement in gross margin and operating loss trajectory over the next 2-3 quarters.

Key Decisions for Investors

• Short TLRY on rallies; use a 1-3 month horizon and cover if price action is driven by credible U.S. reform headlines rather than sector sympathy. Risk/reward is favorable because fundamental disappointment can keep compounding even if the stock is already down sharply.
• If using options, prefer TLRY put spreads 2-4 months out instead of naked short stock to cap squeeze risk from retail flows and policy headlines. Falsifier: a material guidance raise or margin inflection next earnings.
• Avoid rotating into the broader cannabis beta basket (MJ/MSOS) as a substitute for TLRY long exposure until there is evidence of sector-wide gross margin stabilization; the more likely second-order effect is further multiple compression across the group.
• Watch for any financing, asset-sale, or equity issuance language over the next quarter; that would confirm the balance-sheet overhang and create a cleaner short entry on any relief rally.